Projects per year
Aberrant expression of the proto-oncogene BCL6 is a driver of tumorigenesis in diffuse large B cell lymphoma (DLBCL). Mice overexpressing BCL6 from the B cell-specific immunoglobulin heavy chain μ intron promoter (Iμ-Bcl6Tg/+) develop B cell lymphomas with features typical of human DLBCL. While the development of B cell lymphoma in these mice is tightly controlled by T cells, the mechanisms of this immune surveillance are poorly understood. Here we show that CD4 T cells contribute to the control of lymphoproliferative disease in lymphoma-prone Iμ-Bcl6Tg/+ mice. We reveal that this CD4 T cell immuno-surveillance requires signaling by the co-stimulatory molecule CD137 ligand (CD137L; also known as 4-1BBL), which may promote the transition of pre-malignant B cells with an activated phenotype into the germinal center stage via reverse signaling, preventing their hazardous accumulation. Thus, CD137L-mediated CD4 T cell immuno-surveillance adds another layer of protection against B cell malignancy to that provided by CD8 T cell cytotoxicity.
- B cell malignancy
- CD4 T cells
- tumor immunity
1/01/20 → 31/12/22
The role of IL21 in integrating proliferation, migration and differentiation following B cell activation.
1/01/18 → 30/06/23
Christine Findlay (Manager)Faculty of Medicine Nursing and Health Sciences Research Platforms
Deanna Deveson (Manager)Faculty of Medicine Nursing and Health Sciences Research Platforms
Andrew Fryga (Manager)Faculty of Medicine Nursing and Health Sciences Research Platforms